FLAMINGO: how much rosier can antiretroviral therapy get?
FLAMINGO: how much rosier can antiretroviral therapy get?
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
In The Lancet, Bonaventura Clotet and colleagues present the FLAMINGO study, in which 484 antiretroviral-naive HIV-infected patients were randomly assigned to receive two nucleos(t)ide reverse transcriptase inhibitors (tenofovir-emtricitabine or abacavir-lamivudine) plus either dolutegravir (50 mg) or the boosted protease inhibitor darunavir (800 m...
Alternative Titles
Full title
FLAMINGO: how much rosier can antiretroviral therapy get?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1542003859
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1542003859
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(14)60447-5
